Tag Archives: Mark Pykett

Business, Finance, Occupation & Industry

Navidea Biopharmaceuticals Retains Stern IR for Investor Relations Services

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Navidea Biopharmaceuticals Retains Stern IR for Investor Relations Services

DUBLIN, Ohio–(BUSINESS WIRE)– Navidea Biopharmaceuticals (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has retained Stern Investor Relations, Inc. to provide strategic advisory services and execute and enhance the Company’s investor relations program. Stern IR is a full service investor relations firm specializing in entrepreneurial healthcare and biotechnology companies.

The firm will provide strategic counsel and execution to advance Navidea’s leadership in innovative, precision diagnostics that improve diagnostic accuracy, clinical decision-making and patient care. Stern’s focus will be to improve and broaden the Company’s exposure within the investment community and support its efforts to establish additional partnerships and relationships in the healthcare and financial communities.

“As we move forward in advancing the field of precision diagnostics through the commercialization of the recently approved Lymphoseek® and the continued progression and expansion of our promising pipeline of radiopharmaceuticals in oncology and neurology, we are very pleased to be working with an experienced, well-regarded firm like Stern IR at this pivotal period of growth for Navidea,” said Mark Pykett, President and CEO of Navidea.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek®, NAV4694, NAV5001 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

About Stern Investor Relations

Stern Investor Relations, Inc. (Stern IR) is a leading investor relations firm specializing in investor relations consulting services to healthcare and biotechnology companies in the U.S. and around the world. Since its inception in 1998, Stern IR has worked with more than 200 biotechnology, specialty pharmaceuticals, devices, healthcare services and industrial biotechnology companies in all stages of development, including bellwethers in the industry, small‐ and mid‐cap companies, recent IPOs and private companies. Stern IR is based in New York City. For more information, please visit www.sternir.com.

…read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Navidea and Collaborator Molecular Neuroimaging Enroll First Subject in NAV5001 Clinical Trial

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Navidea and Collaborator Molecular Neuroimaging Enroll First Subject in NAV5001 Clinical Trial

Study to investigate [ 123 I] NAV5001 SPECT imaging as a tool to evaluate dopamine transporters in the brain as start of program in Dementia with Lewy Bodies

DUBLIN, Ohio–(BUSINESS WIRE)– Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators at Molecular Neuroimaging, LLC (MNI) in New Haven, CT have enrolled the first subject in a clinical study to investigate the performance of [123I]NAV5001 in a SPECT imaging procedure in connection with Navidea’s program to evaluate NAV5001 in Dementia with Lewy Bodies (DLB).

“This collaborative investigator-initiated study is an important first step in recommencing a full clinical development program for NAV5001 since our in-licensing this candidate in late 2012,” said Dr. Mark Pykett, Navidea’s President and CEO. “Collaborations such as this are integral to Navidea’s strategy to efficiently and effectively advance the development of our promising radiopharmaceutical pipeline and representative of our focus of being a leader in the field of precision diagnostics.”

“The study is the first leg of our program to evaluate the utility of NAV5001 in DLB, the leading form of dementia after Alzheimer’s disease and an important potential indication for NAV5001 medically and commercially,” commented Cornelia Reininger, MD, PhD, Navidea’s Senior Vice President and Chief Medical Officer. “During 2013, we look forward to following this study with the initiation of a Company-sponsored Phase 2b study of NAV5001 in DLB as well as the anticipated start of the Company’s pivotal parallel Phase 3 registration studies of NAV5001 as an aid in the differential diagnosis of Parkinsonian syndromes.”

The goal of this single center, open-label, investigator-initiated study will be to assess the distribution, safety and tolerability of NAV5001 as an agent to evaluate the integrity of the dopamine transporters in the brain, using healthy volunteers. NAV5001 is an investigational radiopharmaceutical imaging agent being developed as an aid in the differential diagnosis of Parkinsonian syndromes, including Parkinson’s disease (PD) and other movement disorders, as well as Dementia with Lewy Bodies (DLB). Danna Jennings, MD, Clinical Research Director at MNI will lead the investigator-initiated clinical study.

About NAV5001

[123I]NAV5001 is a patented, novel, small molecule radiopharmaceutical used with single photon emission computed tomography (SPECT) imaging to identify the status of specific regions in the brains of patients suspected of having Parkinson’s disease. The …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference


Chief Executive Officer to Provide Business and Development Program Updates

DUBLIN, Ohio–(BUSINESS WIRE)– Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, Navidea’s President and Chief Executive Officer, will participate at the Future Leaders in the Biotech Industry Conference on April 5, 2013 at the Millennium Broadway Hotel & Conference Center, New York, NY. Dr. Pykett will provide an update of the Company and its development programs at 9:30 AM EDT.

Investors and the public are invited to listen to a live webcast of Dr. Pykett’s presentation at http://www.media-server.com/m/p/exttmn6v. Following the conference, the webcast will be archived for approximately 30 days.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek®, NAV4694, NAV5001 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Sr. VP & CFO

KEYWORDS:   United States  North America  Ohio

INDUSTRY KEYWORDS:

The article Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
…read more
Source: FULL ARTICLE at DailyFinance